Dako is Official Platinum Sponsor of Global Pathology Congress for Second Straight Year
Dako, an Agilent Technologies company and worldwide provider of cancer diagnostics, is again the official Platinum Sponsor of this year’s annual meeting of the United States and Canadian Academy of Pathology (USCAP) at the San Diego Convention Center in San Diego, Calif.
Dako will showcase its entire portfolio of integrated pathology solutions, designed with pathologists and laboratory staff in mind, at exhibition booth No. 522. Visitors will be able to see demonstrations of all Dako’s solutions, including the newest, Dako Omnis, which automates both IHC and ISH processes and enables entire patient cases to be processed simultaneously. This allows pathologists to make quicker, more informed diagnoses to aid oncologists in treatment decisions with less waiting time for patients.
Other new products from Agilent’s Diagnostics and Genomics businesses will be featured at the booth, including SureFISH probes and information on next-generation sequencing.
Attendees will also be able to learn about Dako’s entire range of high-quality antibodies, instruments and software designed to help meet the needs of the modern pathology lab.
A new review titled “Immunohistochemistry in Prostate Pathology,” written by global prostate pathology experts Glen Kristiansen, M.D., and Jonathan Epstein, M.D., will be handed out at the booth. The paper concisely illustrates how IHC can contribute substantially to diagnostic prostate pathology and gives prostate pathologists a comprehensive reference of various prostate markers.
Booth attendees can also receive a new white paper on the groundbreaking Dynamic Gap IHC staining technology. The paper explains why this new technology, available exclusively on Dako Omnis, is so important for consistent and reproducible IHC staining.
On Tuesday, March 4, Dako will co-host an Exhibitor Seminar in cooperation with one of its pharmaceutical partners, Bristol-Myers Squibb, titled “Exploring Immune-Based Biomarkers in Oncology,” from 5:30-7:30 p.m. in Room 29D. This seminar will update the pathology community on the importance of emerging immune therapies for the treatment of cancer and the need to establish a better understanding of how immune-based biomarkers may potentially serve a role in selecting patients for these new therapies.
“Dako is proud to once again be the official Platinum Sponsor of the USCAP,” said Britt Meelby Jensen, Dako general manager and Agilent vice president. “This is one of the best-organized and most-attended pathology congresses, and we see it as a key opportunity to reach the pathology community. We look forward to meeting with the many attendees who share our commitment to the fight against cancer.”
Attendees at the USCAP are pathologists and other key decision makers in the field of pathology and the related specialties of toxicology, oncology and immunology from hospitals, private laboratories and governmental entities. The annual meeting of the USCAP is the largest gathering of physician-pathologists in the world.
About Dako - An Agilent Technologies Company
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako’s reagents, instruments, software and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients. Dako became part of Agilent Technologies in 2012. Information about Dako is available at www.dako.com
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com.
On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. The new company is named Keysight Technologies, Inc. The separation is expected to be completed in early November 2014.
This news content was configured by WebWire editorial staff. Linking is permitted.